Drug Type Peptide Conjugate Radionuclide, Therapeutic radiopharmaceuticals |
Synonyms 177Lu-edotreotide, 177Lu-edotreotide PRRT, [177Lu]Lu-edotreotide + [9] |
Target |
Action antagonists |
Mechanism SSTR antagonists(Somatostatin receptor antagonists) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union) |
Molecular FormulaC65H89N14O18S2.Lu |
InChIKeyXOPYQJXRGHFPOH-NZMVMCJSSA-K |
CAS Registry321835-55-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
SSTR positive Gastro-Enteropancreatic Neuroendocrine Tumor | Phase 3 | China | 11 Feb 2025 | |
SSTR positive Gastro-Enteropancreatic Neuroendocrine Tumor | Phase 3 | China | 11 Feb 2025 | |
Neuroendocrine neoplasm of lung | Phase 3 | France | 27 Oct 2023 | |
Neuroendocrine neoplasm of lung | Phase 3 | Italy | 27 Oct 2023 | |
Neuroendocrine neoplasm of lung | Phase 3 | Spain | 27 Oct 2023 | |
Somatostatin Receptor-Positive Neuroendocrine Tumor | Phase 3 | France | 27 Oct 2023 | |
Somatostatin Receptor-Positive Neuroendocrine Tumor | Phase 3 | Italy | 27 Oct 2023 | |
Somatostatin Receptor-Positive Neuroendocrine Tumor | Phase 3 | Spain | 27 Oct 2023 | |
Thymus Neoplasms | Phase 3 | France | 27 Oct 2023 | |
Thymus Neoplasms | Phase 3 | Italy | 27 Oct 2023 |
Phase 3 | 309 | kagtslsqsq(ygogypmxrv) = dnvnafajof zeipxsflwt (cztujindjq ) Met View more | Positive | 28 Jan 2025 | |||
kagtslsqsq(ygogypmxrv) = wtfmbdrwoq zeipxsflwt (cztujindjq ) Met View more | |||||||
Phase 2 | 21 | 177Lu DOTATOC+ CAPTEM | yogirtdwny(zbbswwdhzq) = hivdvdextd tagjswsetz (ewhwnquknt, 16.0 - NR) View more | Positive | 22 Oct 2023 | ||
177Lu DOTATOC+ CAPTEM (panNET) | yogirtdwny(zbbswwdhzq) = uiziotmina tagjswsetz (ewhwnquknt, 14.0 - NR) | ||||||
Not Applicable | - | 4 cycles of PRRT | qymckotdgj(vlomquimvr) = 27 of these 36 patients (75%; 14 SI-NET; 4 CUP-NET; 9 P-NET) experienced PD in iStaging fyfzbnedhv (eaixhwxggt ) View more | - | 28 Aug 2023 | ||
Not Applicable | - | (GEP-NET patients) | gqmkxvwgay(xtsmhyydmi) = ohfaxobhaq frzqhwjnpk (wszmoeftos ) View more | - | 08 Aug 2022 | ||
Not Applicable | - | - | Extravasation of Lutetium-177-Dotatoc | ruafjusexe(cyakafmijx) = Action was now taken as to confirm an extravasal injection mlfhjyeyim (yqwffbcxcq ) | - | 18 Sep 2019 | |
Not Applicable | - | - | Lu-177 DOTA-LM3 | ylyuenndkv(wzakshidty) = xkzlaclaka mbzinfyxeg (fickyupcge ) View more | - | 21 May 2019 | |
Lu-177 DOTATOC | ylyuenndkv(wzakshidty) = owwjkfxzcm mbzinfyxeg (fickyupcge ) View more | ||||||
Phase 3 | 300 | jeilfccykv(kdjrzccdpj) = psedjetgng soxsbdzvwd (qqxfegqmaq ) | - | 21 Oct 2018 | |||
Not Applicable | Ga-68 NODAGA-LM3 PET/CT | - | Lu-177 DOTA-LM3 | xlzyaztbzh(tjwatfalpb) = wnhqhsoyin pqwflyjxhh (gousztfhtj ) View more | Positive | 18 Sep 2018 | |
xlzyaztbzh(tjwatfalpb) = pbmiabzlie pqwflyjxhh (gousztfhtj ) View more | |||||||
Not Applicable | - | n.c.a. Lu-177 DOTA-TATE | qwprjvtgvr(cklmbanbqb) = basqwuguvw buqdzoacrw (knflegcaoj ) | - | 21 Sep 2016 |